Last update 26 May 2025

Elcatonin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Elcatonin (JP17/INN), HC 58, HC-58
+ [7]
Target
Action
inhibitors
Mechanism
CALCR inhibitors(Calcitonin receptor inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (15 Jun 1982),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC148H244N42O47
InChIKeyDDPFHDCZUJFNAT-PZPWKVFESA-N
CAS Registry60731-46-6

External Link

KEGGWikiATCDrug Bank
D03287Elcatonin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Familial Paget's Disease of Bone
Japan
07 Feb 2006
Hypercalcemia
China
22 Jun 1999
Osteoporosis
Japan
15 Jun 1982
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemiplegiaPhase 2
Japan
01 Jul 2012
StrokePhase 2
Japan
01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
qyftfdmdba(mjvdumrqfe) = xcjlttulyu hayshmlnxh (abhcoqrdui )
Negative
23 Oct 2018
(Control Group)
qyftfdmdba(mjvdumrqfe) = lrpmktqdjc hayshmlnxh (abhcoqrdui )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free